Therefore, we performed the current in vivo study and Figure 3A–E indicated regorafenib not only reduced ERK, NF-κB, and AKT phosphorylation but also triggered expression of active Caspase-9, -8, and -3 in SK-Hep1/luc2 and Hep3B 2.1-7 tumor bearing mice. The gene discussed is CASP9; the disease is neoplasm.